FierceBiotech 8 abr 2026 With $2B Novo deal in the books, Vivtex isn't 'limited to being just a drug delivery company': CEO
FierceBiotech 8 abr 2026 Astellas unearths Dyno muscle disorder AAV capsid with $15M option agreement
FierceBiotech 8 abr 2026 Akari locks arms with WuXi XDC to develop and manufacture novel ADC treatment
FierceBiotech 8 abr 2026 Jeito hails $1.2B as 'largest raise ever' for independent biopharma-focused European fund
FierceBiotech 8 abr 2026 OrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugates
FierceBiotech 8 abr 2026 With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'
FierceBiotech 7 abr 2026 Lilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinic
FierceBiotech 7 abr 2026 Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study
FierceBiotech 6 abr 2026 Takeda tears up Denali partnership, returning dementia asset amid restructuring
FierceBiotech 6 abr 2026 AI model designs new treatment candidate for opioid addiction that cuts cravings in rats
FierceBiotech 6 abr 2026 With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine
FierceBiotech 6 abr 2026 US, UK regulators bolster medical device collaboration while lifting tariffs